George Thom

George Thom is Director of RNA Therapy team within Discovery Sciences at AstraZeneca, Cambridge. At AstraZeneca, he has spent 17 years developing technology platforms to isolate, or target, antibodies to specific tissues and targets e.g. isolation of the anti-IL-13 antibody, Tralokinumab used to treat atopic dermatitis or developing of targeting biologics to cross the blood brain barrier (BBB). More recently, George joined the In Vivo Expression Biologics (IVEB) team to help develop the mRNA platform for utility within vaccines and therapeutic protein settings.